PharmEasy secures ₹1,300 crore from Ranjan Pai and an oversubscribed ₹3,500 crore rights issue.
- Ranjan Pai, Chairman of Manipal Education and Medical Group, has made a noteworthy financial commitment by investing a substantial INR 1,300 crore in the recent PharmEasy rights issue through his family office, according to insider sources.
- This significant capital infusion contributes to PharmEasy’s ambitious fundraising effort, targeting INR 3,500 crore through a rights issue.
- The fundraising initiative experienced overwhelming demand, ultimately resulting in an oversubscription at INR 3,950 crore, indicating strong investor interest and confidence in PharmEasy’s prospects.
Fundraising Breakdown:
Total Fund- Raised – INR 3,500 Crore
Fund Raised through Existing Shareholders – INR 2,200 Crore
Through Ranjan Pai – INR 1,300 Crore
Ranjan Pai Emerges as Largest Shareholder:
- Ranjan Pai’s Dominant Stake:
- Substantial investment of INR 1,300 crore in PharmEasy’s recent rights issue.
- Emerged as the largest shareholder with an estimated 13-14% stake.
- Signifies Pai’s strong confidence in PharmEasy’s potential and strategic direction.
- Ownership Dynamics:
- Reflects a significant shift in ownership structure following Pai’s investment.
- Highlights the strategic importance of Pai’s involvement in shaping the company’s future.
- Prosus, an institutional investor, holds the position of the second-largest shareholder.
- Strategic Decision-Making:
- Pai’s increased stake suggests a potential impact on strategic decision-making.
- Indicates a deeper level of involvement, possibly extending to board participation.
Shareholding Structure and Board Involvement:
The specific shareholding structure of API Holdings, PharmEasy’s parent company, is expected to become clearer upon the receipt of funds.
Additionally, sources suggest that Ranjan Pai is poised to join the board of API Holdings, indicating his deepening involvement in the company’s strategic decision-making. However, there are no immediate plans for Pai to further increase his stake in the company.
Debt Management and Profitability:
PharmEasy’s recent fundraising initiative comes at a crucial time as the company addresses its debt, amounting to $300 million from Goldman Sachs. A portion of the newly acquired funds is earmarked to reduce this debt burden.
Notably, PharmEasy achieved profitability in the first half of 2023-24, posting a cumulative EBITDA of Rs 60 crore for the months of April to September 2023. This positive financial performance underscores the company’s resilience and strategic acumen. PharmEasy unlisted share prices start from Rs. 8.1. Start investing now!
Prosus Expresses Confidence Despite Write-Downs:
Despite recent write-downs, including a $118 million adjustment for PharmEasy in the first half of FY24.
Basil Sgourdos, Group CFO and Executive Director, stated, “We actually participated in that round, which expresses our confidence in the business going forward. We own 13% of PharmEasy. We haven’t disclosed the full value of the company.” This reaffirms Prosus’ belief in PharmEasy’s long-term viability.
Conclusion:
The successful completion of the rights issue and Ranjan Pai’s substantial investment position PharmEasy for accelerated growth and strategic expansion.
With a strengthened financial position, the company is well-equipped to navigate its debt challenges and capitalize on emerging opportunities in the dynamic healthcare sector.
Get in Touch with us:
For any query/ personal assistance feel free to reach out at support@Altiusinvestech.com or call us at +91-8240614850.
To know, more about Unlisted Company. Click here – https://altiusinvestech.com/blog/what-is-listed-and-unlisted-company
You can also checkout the list of Best 5 Unlisted Shares to Buy in India
For Direct Trading, Visit – https://trade.altiusinvestech.com/.
To know more about How to apply for an IPO? Click- https://altiusinvestech.com/blog/how-to-apply-for-an-ipo/
ALSO READ Our Other Blogs: